Amylyx Pharmaceuticals (AMLX) Projected to Release Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3810) per share and revenue of $0.06 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post ($1.48) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock traded up $0.57 during mid-day trading on Tuesday, reaching $28.61. The company’s stock had a trading volume of 40,748 shares, compared to its average volume of 1,618,640. The business’s 50 day simple moving average is $30.68 and its 200 day simple moving average is $20.13. Amylyx Pharmaceuticals has a 12 month low of $10.83 and a 12 month high of $41.14. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -20.01 and a beta of -0.10.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, Director M Jr sold 30,000 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the sale, the director owned 782,881 shares in the company, valued at approximately $21,685,803.70. The trade was a 3.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Camille Bedrosian sold 10,028 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $32.40, for a total value of $324,907.20. Following the completion of the sale, the insider owned 278,064 shares in the company, valued at $9,009,273.60. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 60,374 shares of company stock valued at $1,815,257 over the last 90 days. 10.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AMLX shares. Mizuho increased their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Citigroup raised their target price on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, October 15th. Finally, Guggenheim lifted their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $40.71.

Amylyx Pharmaceuticals Company Profile